The Observation Of17-β Estradiol With Drospirenone For The Treatment Of Menopausal Syndrome

Purpose: To observe the therapeutical effect of17β-estradiol plusdrospirenone in the treatment of menopausal syndrome.. And to explore themechanism and the advantage of17β-estradiol and DRSP treatment ofmenopausal syndrome.Method:17β-estradiol plus DRSP treatment was applied to76cases ofmenopausal syndrome women suffering from menopausal syndrome for3months, and the effects were observed.Result：The patient’s menopausal symptoms gradually eased with extensionof time with the medication. After the end of the three courses of medication,apart from the skin discomfort symptom was not statistically significant，theremaining12symptoms were significant (P <0.05) or statistically significant (P<0.01). Hot flashes was statistically significant (P <0.01) as soon as the end ofthe first course of treatment medication. Serum FSH and E2changes werestatistically significant (P <0.01) after the end of treatment, and the E2level wasclose to the level of the follicular phase after treatment. The total cholesterolchange was statistically significant (P<0.05), and changes in high densitylipoprotein and low-density lipoprotein had no statistically significant, but theformer was an upward trend in the treatment process, the latter a downwardtrend in the treatment process.Conclusion:17β-estradiol plus DRSP can effectively relieve menopausal syndrome., and the effects of hot flashes, night sweats, insomnia, forgetfulness,fatigue were especially significant.17β-estradiol and DRSP for a new generationof estrogen and progesterone has some advantages compared with other HRTdrugs.